Wedbush Predicts Weaker Earnings for Stoke Therapeutics

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Wedbush decreased their Q1 2025 earnings estimates for Stoke Therapeutics in a note issued to investors on Wednesday, February 19th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.58) per share for the quarter, down from their prior estimate of ($0.56). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.03) EPS.

Other equities research analysts have also issued research reports about the company. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. HC Wainwright upped their price objective on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Trading Down 6.0 %

Shares of NASDAQ STOK opened at $8.74 on Friday. The business’s 50 day moving average price is $10.62 and its 200 day moving average price is $12.32. Stoke Therapeutics has a 52 week low of $5.20 and a 52 week high of $17.58.

Insider Activity

In related news, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now directly owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jonathan Allan sold 9,696 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $123,914.88. Following the completion of the transaction, the general counsel now directly owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. This represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 in the last quarter. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in STOK. Toronto Dominion Bank acquired a new position in Stoke Therapeutics in the 4th quarter valued at $35,001,000. RTW Investments LP increased its stake in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after acquiring an additional 471,240 shares during the last quarter. Norges Bank acquired a new stake in shares of Stoke Therapeutics in the 4th quarter worth $3,472,000. Tang Capital Management LLC acquired a new stake in shares of Stoke Therapeutics in the 4th quarter worth $3,309,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Stoke Therapeutics in the 4th quarter worth $3,218,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.